“`html
Updated HPV Vaccine Guidance and Changes to childhood Immunization Schedules
The Department of Health and Human Services (HHS) recently announced changes to the recommended childhood vaccine schedule, reducing the number of universally recommended vaccines from 17 to 11. While the Human Papillomavirus (HPV) vaccine remains recommended for all children at age 11 or 12, new guidance suggests a single dose may be sufficient for most individuals. This shift reflects the latest research findings on HPV vaccine effectiveness.
Evolution of HPV Vaccine Recommendations
Initially, the HPV vaccine was administered in a three-dose series. However, research over the past few years demonstrated that a two-dose schedule provided comparable protection. Organizations like the World Health Association,the Advisory Committee on Immunization practices (ACIP),and the Centers for Disease Control and Prevention (CDC) afterward endorsed the two-dose regimen. Recent data now indicates that even a single dose may offer adequate protection.
The ESCUDDO Trial and Gardasil 9 effectiveness
The basis for the single-dose suggestion stems from the ESCUDDO trial, published in the New England Journal of Medicine in December 2025. This study, conducted in Costa Rica from 2017, involved over 20,000 girls aged 12-16 randomly assigned to one of four groups:
- Group 1: One dose of Cervarix (protects against HPV types 16 and 18).
- Group 2: Two doses of Cervarix.
- Group 3: One dose of Gardasil 9 (protects against nine HPV types).
-
More on this